These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 31461670

  • 1. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
    Qiu N, He YF, Zhang SM, Zhan YT, Han GD, Jiang M, He WX, Zhou J, Liang HL, Ao X, Xia HM, Li J, Yang YY, He ZM, Zou ZZ, Li HS.
    Cancer Lett; 2019 Nov 01; 464():25-36. PubMed ID: 31461670
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.
    Ann Oncol; 2010 Feb 01; 21(2):255-262. PubMed ID: 19633047
    [Abstract] [Full Text] [Related]

  • 6. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov 01; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 7. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
    Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA.
    Clin Cancer Res; 2012 Dec 15; 18(24):6784-91. PubMed ID: 23092874
    [Abstract] [Full Text] [Related]

  • 8. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
    Liu J, Pan C, Guo L, Wu M, Guo J, Peng S, Wu Q, Zuo Q.
    J Hematol Oncol; 2016 Aug 31; 9(1):76. PubMed ID: 27581375
    [Abstract] [Full Text] [Related]

  • 9. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, Davies BR.
    Int J Oncol; 2015 Aug 31; 47(2):446-54. PubMed ID: 26095475
    [Abstract] [Full Text] [Related]

  • 10. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y, Wang Z, Jiang Y, Yang C.
    Cancer Lett; 2011 Dec 26; 313(1):54-63. PubMed ID: 21943825
    [Abstract] [Full Text] [Related]

  • 11. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T.
    Sci Rep; 2020 Dec 10; 10(1):21762. PubMed ID: 33303839
    [Abstract] [Full Text] [Related]

  • 12. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG, Jia LT.
    BMC Cancer; 2014 Feb 26; 14():134. PubMed ID: 24571711
    [Abstract] [Full Text] [Related]

  • 13. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.
    Int J Oncol; 2010 Sep 26; 37(3):669-78. PubMed ID: 20664936
    [Abstract] [Full Text] [Related]

  • 14. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
    Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G.
    Br J Cancer; 2012 Apr 10; 106(8):1367-73. PubMed ID: 22454081
    [Abstract] [Full Text] [Related]

  • 15. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H.
    Cancer Sci; 2014 Jul 10; 105(7):779-87. PubMed ID: 24754246
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.
    Liu D, Shi M, Duan C, Chen H, Hu Y, Yang Z, Duan H, Guo N.
    Mol Immunol; 2013 Nov 10; 56(1-2):104-12. PubMed ID: 23711387
    [Abstract] [Full Text] [Related]

  • 17. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
    Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A.
    J Biol Chem; 2015 Aug 28; 290(35):21705-12. PubMed ID: 26152725
    [Abstract] [Full Text] [Related]

  • 18. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2017 Nov 28; 166(1):55-68. PubMed ID: 28702892
    [Abstract] [Full Text] [Related]

  • 19. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.
    Asian Pac J Cancer Prev; 2015 Nov 28; 16(7):2645-51. PubMed ID: 25854340
    [Abstract] [Full Text] [Related]

  • 20. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.
    Breast Cancer Res Treat; 2015 Jan 28; 149(2):373-83. PubMed ID: 25528022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.